Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN
Brierley CK., Rodriguez-Meira A., Bashton M., Hamblin A., Fletcher RS., Fox S., Gaskell C., Jackson A., O'Sullivan J., Murphy LC., SOUSOS N., Enshaei A., Harrison C., Drummond MW., Knapper S., Psaila B., Mead AJ.
62nd ASH Annual Meeting and Exposition. 634.Myeloproliferative Syndromes: Clinical